Dr. Jason Westin is the Director of Lymphoma Clinical Research Program and Section Chief of Aggressive Lymphoma research team at the University of Texas MD Anderson Cancer Center in the Department of Lymphoma and Myeloma. He is the Chair of the ASCO Government Relations Committee, and the Treasurer of the ASCO Association Board of Directors, and the Chair of the ASCO Association Finance Committee. Dr. Westin is also the Director of the Lymphoma Treatment Planning meeting.

His research interests include designing and conducting innovative clinical trials, the development of new drugs and new methods to improve outcomes for patients with lymphoma, and developing methods to integrate translational research including ctDNA and advanced tumor profiling. Dr. Westin believes that clinical research is our best weapon in the fight against cancer, and has designed and conducted numerous investigator initiated clinical trials to find new treatments for cancer.

Dr. Westin has published his research in the New England Journal of Medicine, the Journal of Clinical Oncology, Lancet Oncology, Nature Medicine, Cell, and Blood. He has presented his research at national and international conferences, including the American Society of Hematology, the American Society of Clinical Oncology, the American Association for Cancer Research, the American College of Clinical Pharmacology, the Lymphoma Research Foundation, and in Japan, Thailand, China, Spain, Italy, Portugal, Switzerland, Belgium, Canada, and Peru.

He has received multiple awards to fund his research, including a prestigious Conquer Cancer Foundation Leadership Development Program and a Career Development Award from the American Society of Clinical Oncology, a Hope Foundation Grant from the Southwest Oncology Group, a Waun Ki Hong Award for Team Science, a Paul Calabresi NIH K12 Career Development Award, a Conquer Cancer Foundation Young Investigator Award, an R. Lee Clark Fellow award recognizing America's future cancer leaders, and many others.